BioSpace News Archive

Nanoform Finland Plc announced a proprietary technology that can form biological nanoparticles as small as 50 nm and announced a new near-term business target for 2021 to deliver its first biologics Proof of Concept project for this new technology with a pharmaceutical or biotech partner.

Strong momentum continues: first GMP campaign initiated, first dosing in humans to start before year-end, all near-term business targets set out in IPO to be achieved ahead of schedule, new global major pharma client signed, two new PoC projects started, one more non-GMP line commissioned and a new near-term business target introduced: “First Biologics PoC project in 2021".

BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announced the appointment of Cecilia Hofvander as Senior Director Investor Relations, a new position at BioInvent covering external communications and investor relations.

Approval by MHLW provides new HIF-PH inhibitor treatment option for healthcare providers and adult patients with anemia of CKD not on dialysis

BioInvent International AB’s Extraordinary General Meeting resolved to approve the Board of Directors’ resolution on a directed issue of 29,395,311 new shares and 14,697,655 new warrants to CASI Pharmaceuticals Inc.

FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, “FibroGen”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved EVRENZO ® (roxadustat) for the treatment of anemia of chronic kidney disease (CKD) in adult patients not on dialysis. This marks the second approval in Japan for roxadustat through the Astellas and

Biogen and Sage enter into an agreementto jointly develop and commercialize zuranolone and SAGE-324 in the U.S.

Acerus Pharmaceuticals Corporation (“ Acerus ” or the “ Company ”) (TSX: ASP, OTCQB: ASPCF) is pleased to announce that, further to its press release dated November 25, 2020 with respect to the completion of Acerus’ rights offering (the “ Rights Offering ”), Acerus issued 526,600,000 common shares of Acerus (“ Common Shares ”) under the Rights Offering at a price of $0.025 per share for gross proceeds of approximately $13,165,

Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT) , a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly owned subsidiary Dialco Medical Inc. ( “ Dialco ” ), today announced the details for the Company’s upcoming Virtual Investor Day, scheduled to be held on Friday, December 4, 2

[27-November-2020] Proceeds to fund development of novel and best-in-class therapeutics for eye diseases Charles Semba , MD, joins the company to serve as Chief Medical Officer